If you’ve been told your knee osteoarthritis is simply “wear and tear” and that your only option is pain management until a knee replacement becomes necessary, you’re not alone. But over the past two decades, a growing body of clinical research has examined an alternative treatment approach called dextrose prolotherapy — and the findings have been surprisingly consistent.
This article breaks down the three most important randomized controlled trials on prolotherapy for knee osteoarthritis, what researchers discovered, and why these findings may change how some clinicians think about chronic knee pain.
What Is Dextrose Prolotherapy?
Prolotherapy (short for proliferative therapy) involves injecting a concentrated dextrose (medical glucose) solution into damaged or weakened connective tissue. The goal is to stimulate the body’s healing response by encouraging collagen production and tissue repair.
In knee osteoarthritis, prolotherapy is typically directed at structures such as:
- Ligaments
- Tendon attachments
- Joint capsule tissues
- The knee joint itself
Researchers have proposed that knee OA pain is not caused solely by cartilage loss. Joint instability and ligament laxity may also contribute significantly to pain, abnormal movement, and long-term degeneration. Prolotherapy aims to improve the stability of the knee rather than simply masking symptoms.
The Foundational Trial: Reeves & Hassanein (2000)
Study Overview
Reeves KD and Hassanein KM conducted one of the first randomized, double-blind, placebo-controlled trials examining dextrose prolotherapy for knee osteoarthritis. At the time, this level of study design was extremely uncommon in prolotherapy research.
Participants with knee OA received either:
- Dextrose prolotherapy injections
- Placebo injections
Treatments targeted periarticular structures including ligaments, tendon attachments, and the joint capsule.
Key Findings
- Approximately 40% pain reduction compared to placebo
- 14-degree improvement in knee flexion, representing roughly a 27% increase in range of motion
- 55% improvement in ACL stability, measured objectively with a KT-1000 arthrometer
The ACL stability findings were especially important because they provided measurable, objective evidence of improved joint mechanics — not just patient-reported symptom changes.
Why This Study Mattered
This trial challenged the traditional belief that osteoarthritis is purely a cartilage disease. Instead, it suggested that ligament weakness and joint instability may play a major role in OA pain and dysfunction.
Today, the concept of osteoarthritis as a “whole-joint disease” has become far more accepted, making this study particularly influential in retrospect.
Confirming the Findings: Rabago et al. (2013)
Study Design
More than a decade later, David Rabago and colleagues at the University of Wisconsin conducted a larger and more comprehensive randomized controlled trial involving 90 adults with symptomatic knee osteoarthritis.
Participants were randomized into three groups:
- Dextrose prolotherapy injections
- Saline placebo injections
- Structured at-home exercise program
This design allowed researchers to compare prolotherapy not only against placebo, but also against an active conservative treatment approach.
The Treatment Protocol
The prolotherapy group received both:
- Extra-articular injections
- Intra-articular injections
Treatments were administered at weeks 1, 5, and 9, with optional sessions at weeks 13 and 17. Participants were followed for a full 52 weeks.
Understanding WOMAC Scores
The study used the WOMAC index (Western Ontario and McMaster Universities Osteoarthritis Index), one of the most widely used tools for measuring osteoarthritis severity.
WOMAC evaluates:
- Pain
- Stiffness
- Physical function
Higher scores indicate greater disability and symptom severity.
Key Findings
- 50% of prolotherapy patients achieved clinically meaningful WOMAC improvement
- Only 30% of saline patients achieved the same threshold
- Only 24% of exercise participants achieved similar improvement
- Overall WOMAC improvement in the prolotherapy group was approximately double that of the control groups
These results helped strengthen the evidence supporting prolotherapy as more than a placebo effect.
A Cleaner Replication: Sit et al. (2020)
Study Overview
Rudolf Sit and colleagues in Hong Kong conducted a streamlined randomized controlled trial involving 76 adults aged 45–75 with knee osteoarthritis.
Unlike earlier studies, this protocol focused solely on intra-articular injections, simplifying the treatment design considerably.
The Protocol
Participants received either:
- 25% dextrose prolotherapy injections
- Normal saline injections
Injections were performed at weeks 0, 4, 8, and 16, with follow-up continuing to 52 weeks.
Key Findings
The prolotherapy group demonstrated a 20.9-point improvement in WOMAC composite scores, compared with only 9.4 points in the saline group.
Importantly, the prolotherapy group exceeded the predefined threshold for clinically meaningful improvement, while the saline group did not.
Because of its straightforward two-arm blinded design, this trial is often viewed as one of the cleaner and easier-to-interpret prolotherapy studies.
Comparing the Three Landmark Trials
| Study | Design | Participants | Injection Approach | Follow-Up |
|---|---|---|---|---|
| Reeves & Hassanein (2000) | Dextrose vs placebo | Not specified | Periarticular | Not specified |
| Rabago et al. (2013) | Dextrose vs saline vs exercise | 90 | Extra + intra-articular | 52 weeks |
| Sit et al. (2020) | Dextrose vs saline | 76 | Intra-articular only | 52 weeks |
What the Evidence Suggests
Across all three randomized controlled trials, several consistent findings emerged.
- Meaningful pain reduction
- Improved WOMAC scores
- Better knee function and mobility
- Improved ligament stability
- Sustained benefits lasting up to one year
- No serious adverse events reported
While larger trials would further strengthen the evidence base, current research suggests prolotherapy may offer a legitimate non-surgical treatment option for some patients with knee osteoarthritis.
The Bigger Picture
These studies reflect a broader shift in how clinicians and researchers view osteoarthritis. Rather than seeing OA strictly as cartilage degeneration, many experts now recognize it as a complex whole-joint condition involving ligaments, tendons, joint capsules, inflammation, and biomechanics.
Dextrose prolotherapy fits within this evolving understanding by targeting connective tissue stability and mechanical function — areas that traditional pain management approaches often ignore.
Although prolotherapy is still considered outside mainstream orthopedic practice in many settings, the research supporting it is more substantial than many patients realize.
Primary Sources
- Reeves KD, Hassanein KM. Randomized Prospective Double-Blind Placebo-Controlled Study of Dextrose Prolotherapy for Knee Osteoarthritis with Ligament Laxity. 2000.
- Rabago D, et al. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Annals of Family Medicine. 2013.
- Sit RWS, et al. Intra-articular dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Annals of Family Medicine. 2020.